The agreement facilitates the adoption of ChromX by scientists and users of resins, columns, and chromatography systems into their downstream process development workflows for the benefit of accelerated development timelines and improved process robustness.
Uppsala, Sweden and Karlsruhe, Germany – February 26, 2020 – GE Healthcare Life Sciences and GoSilico, a software company, have signed an agreement to co-market GoSilico’s ChromX chromatography modeling software and contract modeling services in the United States in the initial phase. The agreement facilitates the adoption of ChromX by scientists and users of resins, columns, and chromatography systems into their downstream process development workflows for the benefit of accelerated development timelines and improved process robustness.
ChromX is a mechanistic modeling software for preparative liquid chromatography processes. The tool simulates and predicts chromatographic performance, enabling a deeper understanding of the outcome of future purification processes. The software reduces the number of experiments needed during the process development, creating substantial time savings in downstream process development.
Photo: A user of ÄKTA pure chromatography system performs a chromatography simulation with ChromX (credits: GoSilico)
Mechanistic modeling of chromatography is a computer-aided method based on mathematical descriptions of the physiochemical transport and interactions that occur during chromatography. The technology can be used as a risk assessment tool to guide process characterization efforts, predicting the impact of variability on process performance and explaining deviations in manufacturing. It can also be used to predict scale-up from lab scale columns to process columns and for scale-down model qualification.
Sofie Stille, General Manager Resins at GE Healthcare Life Sciences, says: “As process development becomes more data and simulation driven, mechanistic modeling is proving to be an important tool. Together with GoSilico, we aim to support our customers achieve efficient and robust process outcomes.”
Dr. Thiemo Huuk, CEO and co-founder of GoSilico, says: “Mechanistic models accelerate process development and can leverage benefits along the entire product life cycle. Together with GE Healthcare Life Sciences, we will empower our customers in the United States to digitalize downstream development even faster and to boost the added value.”
About GE Healthcare Life Sciences
GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.
GoSilico paves the way towards digital process development in the pharmaceutical industry. Their digital twins of chromatography processes enable pharmaceutical companies to simulate chromatography processes on the computer. These models are applicable throughout the whole drug development life cycle: Early stage process design, late stage process characterization and technology transfer, up to root-cause investigations in manufacturing. GoSilico’s simulation technology ChromX is offered as a software solution as well as a contract development service. Founded in 2016, GoSilico today serves more than half of the global top ten biopharmaceutical companies. Visit our website https://gosilico.com/ for more information.
GE Healthcare Life Sciences
Dr. Teresa Baumann